G Pöch

849 total citations
18 papers, 699 citations indexed

About

G Pöch is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Neurology. According to data from OpenAlex, G Pöch has authored 18 papers receiving a total of 699 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 5 papers in Pathology and Forensic Medicine and 3 papers in Neurology. Recurrent topics in G Pöch's work include Cancer Mechanisms and Therapy (4 papers), Melanoma and MAPK Pathways (3 papers) and thermodynamics and calorimetric analyses (3 papers). G Pöch is often cited by papers focused on Cancer Mechanisms and Therapy (4 papers), Melanoma and MAPK Pathways (3 papers) and thermodynamics and calorimetric analyses (3 papers). G Pöch collaborates with scholars based in United States, Argentina and Austria. G Pöch's co-authors include W. R. Kukovetz, Allison Marlow, Clive Morris, Lorelei J. Hanson, Sabine Eckhardt, Lara Maloney, Stephen Leong, David M. Wilson, Laura Q.M. Chow and Katie Kane and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Journal of Medicinal Chemistry.

In The Last Decade

G Pöch

18 papers receiving 684 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
G Pöch United States	7	464	280	128	74	64	18	699
Danny Tam United States	14	449 1.0×	144 0.5×	135 1.1×	76 1.0×	119 1.9×	25	870
Charles W. Bruseo Switzerland	10	519 1.1×	167 0.6×	56 0.4×	52 0.7×	35 0.5×	16	679
Carla L. Van Den Berg United States	15	586 1.3×	284 1.0×	62 0.5×	48 0.6×	36 0.6×	18	768
Sadao Kuromitsu Japan	19	500 1.1×	214 0.8×	75 0.6×	195 2.6×	118 1.8×	39	1.1k
Elisa Sala Italy	17	373 0.8×	435 1.6×	288 2.3×	84 1.1×	41 0.6×	46	842
Anthony Tao United States	9	624 1.3×	388 1.4×	268 2.1×	165 2.2×	30 0.5×	14	920
Silvia Mateo‐Lozano Spain	19	511 1.1×	263 0.9×	119 0.9×	308 4.2×	70 1.1×	26	929
Sudeep Chandra United States	13	242 0.5×	155 0.6×	40 0.3×	89 1.2×	19 0.3×	23	672
Kevin J. Basile United States	10	434 0.9×	248 0.9×	61 0.5×	26 0.4×	28 0.4×	10	572
Mary Guckert United States	13	509 1.1×	462 1.6×	59 0.5×	76 1.0×	52 0.8×	18	808

Countries citing papers authored by G Pöch

Since Specialization

Citations

This map shows the geographic impact of G Pöch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G Pöch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G Pöch more than expected).

Fields of papers citing papers by G Pöch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G Pöch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G Pöch. The network helps show where G Pöch may publish in the future.

Co-authorship network of co-authors of G Pöch

This figure shows the co-authorship network connecting the top 25 collaborators of G Pöch. A scholar is included among the top collaborators of G Pöch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G Pöch. G Pöch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Lee, Patrice A., Eli Wallace, Allison Marlow, et al.. (2010). Abstract 2515: Preclinical Development of ARRY-162, A Potent and Selective MEK 1/2 Inhibitor. Cancer Research. 70(8_Supplement). 2515–2515. 28 indexed citations

Adjei, Alex A., Roger B. Cohen, Wilbur A. Franklin, et al.. (2008). Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers. Journal of Clinical Oncology. 26(13). 2139–2146. 476 indexed citations

Huérou, Yvan Le, Indrani W. Gunawardana, Allen A. Thomas, et al.. (2007). Prodrug thiamine analogs as inhibitors of the enzyme transketolase. Bioorganic & Medicinal Chemistry Letters. 18(2). 505–508. 20 indexed citations

Wallace, Eli M., Joseph P. Lyssikatos, James F. Blake, et al.. (2005). Potent and Selective Mitogen-Activated Protein Kinase Kinase (MEK) 1,2 Inhibitors. 1. 4-(4-Bromo-2-fluorophenylamino)-1- methylpyridin-2(1H)-ones. Journal of Medicinal Chemistry. 49(2). 441–444. 34 indexed citations

Yeh, Tammie C., et al.. (2004). 368 Demonstration of broad in vivo anti-tumor activity of ARRY-142886 (AZD-6244), a potent and selective MEK inhibitor. European Journal of Cancer Supplements. 2(8). 111–111. 3 indexed citations

Pöch, G, Kevin Litwiler, Joseph P. Lyssikatos, et al.. (2004). 342 Anti-tumor activity, pharmacokinetic and pharmacodynamic effects of the MEK inhibitor ARRY-142886 (AZD6244) in a BxPC3 pancreatic tumor xenograft model. European Journal of Cancer Supplements. 2(8). 103–104. 3 indexed citations

Holzmann, S., P. Dittrich, & G Pöch. (1999). Dose-response curves of vasorelaxants: computerized calculation of combination effects using the example of nicorandil. Journal of clinical and basic cardiology. 2(1). 96–98. 5 indexed citations

Kukovetz, W. R., S. Holzmann, & G Pöch. (1992). Molecular Mechanism of Action of Nicorandil. Journal of Cardiovascular Pharmacology. 20. S1–7. 60 indexed citations

Pöch, G, et al.. (1983). Evaluation of the type of overadditive drug interaction under various experimental conditions: differentiation of sequential from functional synergism in dose response studies.. PubMed. 4(6). 371–7. 4 indexed citations

10.

Pöch, G. (1981). [Quantitative estimation of potentiating or inhibitory effects of similarly acting drugs in combination. Advantages of a dose-response curve method over the isoboles-method (author's transl)].. PubMed. 31(7). 1135–40. 4 indexed citations

11.

Pöch, G. (1980). Quantitation of increase in maximum drug response caused by potentiating agents.. PubMed. 30(8). 1310–1. 3 indexed citations

12.

Pöch, G. (1980). Dose factor of potentiation derived from isoboles.. PubMed. 30(12). 2195–6. 5 indexed citations

13.

Pöch, G, et al.. (1974). [Role of cyclic AMP in coronary circulation].. PubMed. 25(12). 515–7. 1 indexed citations

14.

Sica, R. E. P., et al.. (1973). An electrophysiological investigation of skeletal muscle in Parkinson's disease. Journal of the Neurological Sciences. 18(4). 411–420. 10 indexed citations

15.

Kukovetz, W. R. & G Pöch. (1972). The positive inotropic effect of cyclic AMP.. PubMed. 1. 261–90. 32 indexed citations

16.

Pöch, G, et al.. (1971). Hypertrophia musculorum vera. Journal of the Neurological Sciences. 12(1). 53–61. 4 indexed citations

17.

Pöch, G & W. R. Kukovetz. (1969). [On the mechanism of the cardiac effects of 2-bromo-LSD].. PubMed. 263(1). 244–5. 3 indexed citations

18.

Pöch, G, et al.. (1969). [Mechanism of action of papaverine on isolated coronary vessels].. PubMed. 264(3). 262–3. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact